Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective
Mayo Clinic
Oncotarget | February 3, 2016 | Volume: 7 | Issue: 11 | Pages: 13260-13264
10.18632/oncotarget.7177
| PMID 26848626